<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283023</url>
  </required_header>
  <id_info>
    <org_study_id>RH-CMR-003</org_study_id>
    <secondary_id>RVH-CMR-003 grant</secondary_id>
    <nct_id>NCT00283023</nct_id>
  </id_info>
  <brief_title>Oligodendrocyte Progenitor Cell Culture From Human Brain</brief_title>
  <official_title>Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent developments in the understanding of stem- and progenitor cell differentiation raises&#xD;
      hopes that brain damage in chronic neurological diseases may become repaired by systemic or&#xD;
      focal transplantation of such cells. Clinical trials of stem- or progenitor cell&#xD;
      transplantation in multiple sclerosis are currently premature. The researchers developed a&#xD;
      protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment&#xD;
      of demyelinating disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient&#xD;
      with Multiple sclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cell culture</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oligodendrocyte progenitor cell differentiation</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Demyelinating Diseases</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oligodendrocyte progenitor cell culture/craniotomy</intervention_name>
    <description>Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Rajavithi Oligodendrocyte progenitor cell culture protocol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 20-65 years of age&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Has elective craniotomy surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV, hepatitis, and other central nervous system (CNS) infections&#xD;
&#xD;
          -  Dementia, Alzheimer disease, and neurodegenerative disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Subsai Kongsaengdao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Neurology, Department of Medicine, Rajavithi Hospital : Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistant Professor Subsai Kongsaengdao</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <name_title>Assistant Professor Subsai Kongsaengdao</name_title>
    <organization>Rajavithi Hospital</organization>
  </responsible_party>
  <keyword>All selective craniotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Demyelinating Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

